https://marlin-prod.literatumonline.com/pb-assets/Lancet/pdfs/S0140673620316044.pdf
Great news. Skimmed it but will read through most of it later. Another candidate for phase III is excellent news and increases our chances of finding something to get to or close to effective herd immunity
Safety is a huge barrier to cross but efficacy is the main one. But if they're testing this out in South Africa and Brazil which aren't doing great in terms of cases then hopefully some of the vulnerable there can benefit alongside establishing proof of concept
A couple of interesting points in there that I can spot
- the only really serious event was in the control group with the meningitis vaccine was one patient getting hemolytic anemia, most of the vaccine candidate group were fine with paracetamol. The aches, pain, headache, myalgia rates are pretty high (even if they are mild and self-limiting) though a lot less with the booster.
- they're highlighting the fact that both antibodies (humoral immunity) and T-cells (cellular immunity) were elevated with initial dose but the latter was not increased with a second, booster dose. Just wondering here for any of the scientists or immunology buffs here whether there is precedence for that in terms of other effective vaccines?
- neutropenia (drop in neutrophil count) was mentioned as a transient response in 46% of the ChAdOx1 nCoV-19 group. They didn't quantify that but just thinking about cancer patients or others who might be vulnerable from a sepsis point of view as to whether that has any clinical implications
Great news. Skimmed it but will read through most of it later. Another candidate for phase III is excellent news and increases our chances of finding something to get to or close to effective herd immunity
Safety is a huge barrier to cross but efficacy is the main one. But if they're testing this out in South Africa and Brazil which aren't doing great in terms of cases then hopefully some of the vulnerable there can benefit alongside establishing proof of concept
A couple of interesting points in there that I can spot
- the only really serious event was in the control group with the meningitis vaccine was one patient getting hemolytic anemia, most of the vaccine candidate group were fine with paracetamol. The aches, pain, headache, myalgia rates are pretty high (even if they are mild and self-limiting) though a lot less with the booster.
- they're highlighting the fact that both antibodies (humoral immunity) and T-cells (cellular immunity) were elevated with initial dose but the latter was not increased with a second, booster dose. Just wondering here for any of the scientists or immunology buffs here whether there is precedence for that in terms of other effective vaccines?
- neutropenia (drop in neutrophil count) was mentioned as a transient response in 46% of the ChAdOx1 nCoV-19 group. They didn't quantify that but just thinking about cancer patients or others who might be vulnerable from a sepsis point of view as to whether that has any clinical implications